Micro to Macro: The Science of Psilocybin Dosing Protocols

For decades, dosing information for psilocybin came from underground guides and self-reports. Terence McKenna’s “heroic dose” of five dried grams at one end. A microdose of 0.1–0.3g at the other. Everything in between was folklore.

The clinical research era ended that.

From 2006 to 2024, controlled trials using precise synthetic psilocybin gave us something the underground tradition never had: actual dose-response data. And what it shows is more nuanced — and more important — than anything the folklore told us.

The Five Dose Tiers

Tier 1: Microdose — 0.05–0.3g dried (1–3mg synthetic)

Sub-perceptual. No visuals, no dramatic mood shift. The Beckley Foundation’s 2021 Szigeti self-blinded study found modest positive effects on wellbeing — but so did the placebo group. Current evidence does not strongly support therapeutic use at this tier for clinical populations.

Tier 2: Low Dose — 0.5–1g dried (5–10mg synthetic)

Perceptual threshold. Enhanced sensory perception, mild euphoria, increased emotional openness. Not used in landmark clinical trials as primary treatment. Useful for first exposure or high-anxiety individuals.

Tier 3: Moderate Dose — 1.5–3.5g dried (15–25mg synthetic)

This is the clinical gold standard.

Johns Hopkins trials used 20–30mg. Griffiths et al. (2016) found 61% of participants at 30mg had a “complete mystical experience” on the MEQ-30 scale. That mystical experience score turned out to be one of the strongest predictors of long-term therapeutic outcome. Duration: 4–6 hours. This tier produces the largest therapeutic outcomes in controlled research.

Tier 4: High Dose — 4–5g dried (30–40mg synthetic)

Immersive. Full visual geometry, ego dissolution in a substantial proportion of users. Used in trials for existential distress in terminal illness. The COMPASS Pathways trial used 25mg — technically upper moderate — and produced significantly better MADRS outcomes than the 10mg group.

Tier 5: Heroic Dose — 5g+ dried (40mg+ synthetic)

McKenna’s territory. No clinical trials have used doses at this level. This tier exists in the ethnobotanical tradition, not the clinical one. Highest risk. Not part of any evidence-based protocol.

The Set and Setting Multiplier

Every clinical protocol pairs dose with preparation.

Johns Hopkins requires 8 hours of preparatory therapy before the psilocybin session. Matthew Johnson coined the phrase “set and setting multiplier” to describe what they found: the same 25mg dose in an anxious, unsupported context produces a completely different outcome than the same dose in a prepared, supported therapeutic container.

The dose opens the door. The container determines what you find on the other side.

The NEJM Trial: First Real Dose-Comparison Data

The COMPASS Pathways Phase 2b trial (Goodwin et al., 2022) — 233 participants, 22 sites across Europe and North America — was the largest controlled psilocybin trial ever conducted. Three dose conditions: 1mg (active placebo), 10mg, 25mg.

Results at three weeks:

25mg group: Mean reduction of 6.6 points on the MADRS depression scale above placebo

10mg group: 2.5-point difference — statistically significant but clinically modest

The dose-response relationship was unambiguous. 25mg outperformed 10mg by nearly 3x on the primary outcome. This isn’t just convention — it’s evidence-supported as the minimum effective dose for robust antidepressant effects in treatment-resistant depression.

The Conversion Problem

Converting synthetic milligrams to dried mushroom grams is more complicated than it appears.

Psilocybe cubensis contains 0.2–2% psilocybin by dry weight depending on strain, growing conditions, and storage. An average batch at 0.6% gives roughly 6mg per gram — so 3g mushrooms ≈ 18mg synthetic, within the clinical range. But a high-potency strain at 1.5%? Three grams now delivers 45mg — well beyond the most aggressive clinical protocols.

The common “3.5g = ~30mg” conversion rule is an average. Not a reliable guide. Variance between batches and strains can be substantial. This is precisely why clinical research moved to synthetic psilocybin.

Dose Alone Is Never Enough

The Johns Hopkins protocol: 6–8 hours of preparatory therapy before the session. The session itself. Multiple integration sessions in the weeks following.

The theoretical basis is neuroplasticity. Psilocybin opens a window — lasting days to weeks — during which the brain is more receptive to new learning and emotional processing. Carhart-Harris (2021) proposed that this plasticity window is when the genuine therapeutic work occurs. The quality of integration determines whether the acute experience becomes lasting change.

Choosing a 30mg session outside a therapeutic container is not the same intervention as a 30mg session within one.

Dose is the key. The container is the lock.

Full article: https://ootwjournal.com/article-28-psilocybin-dosing-science

OOTW Journal covers the science of psilocybin, consciousness, and plant medicine. Free. No noise.ocybin Dosing Protocols